ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the commercialization and development of neffy, a needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is identified in the European Union and United Kingdom by the trade name EURneffy, and in China by the trade name 优敏速 (Yōumǐnsù). It is the first and only FDA and European Commission-approved needle-free epinephrine product, and also holds approvals in the U.K., Japan, Australia, and China. This product represents the first new delivery method for epinephrine in over 35 years. neffy is a proprietary composition of epinephrine combined with an innovative absorption enhancer called Intravail. This allows neffy to safely deliver epinephrine intranasally at a low dose, achieving exposures comparable to approved injectable products across various dosing conditions, including repeat dosing and allergen challenge. The company believes neffy's "no needle, no injection" approach addresses a significant unmet need, as approximately 40 million people in the U.S. experience Type I allergic reactions.